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Hidradenitis suppurativa (HS) is a chronic, relapsing,
and remitting inflammatory disease of the skin with
significant heritability and racial disposition. The
pathogenesis of HS remains enigmatic, but occlusion
of the terminal hair follicle and dysregulation of the
local innate immune response may contribute to
pathogenesis. Genetic predisposition might also
contribute to disease susceptibility and phenotypic
heterogeneity because mutations in g-secretase have
been found to underlie a minor but characteristic
subset of patients with HS. In this review, we syn-
thesized the current data on g-secretase in HS, eval-
uated its importance in the context of disease
pathobiology, and discussed avenues of future
studies.
Journal of Investigative Dermatology (2021) -, -e-; doi:10.1016/
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Introduction
Hidradenitis suppurativa (HS), also known as acne inversa, is
a chronic, relapsing inflammatory disease of the skin char-
acterized by painful acne-like lesions, nodules, abscesses,
sinus tracts, and scar formation primarily in intertriginous
regions (i.e., axillae, submammary folds, groin). HS is asso-
ciated with a high comorbidity burden and the lowest QOL
among any dermatologic condition, yet it remains under-
recognized and poorly understood (Reddy et al., 2019).
Global incidence of HS varies by country. In the United
States, the incidence of HS is rising. HS is reported in in-
dividuals of all age groups, races, and sexes but shows a
predilection toward African Americans and women. Registry
studies estimate the prevalence of HS at 0.3%, 0.22%, and
0.09% in individuals of African, biracial, and Caucasian
descent, respectively. Furthermore, among these groups, the
prevalence peaks between 20 and 40 years and declines after
50 years (Garg et al., 2017a, 2017b; Sabat et al., 2020).
Despite this demonstrated need, the pathogenesis of HS re-
mains poorly studied.
Studies report that 30e42% of patients with HS report a
positive family history of the disease, which points toward a
potential genetic etiology. A recent Dutch twin cohort study
found a narrow-sense heritability of 77% for HS (van Straalen
et al., 2020). Furthermore, a minority of these patients across
multiple ethnicities have been found to exhibit a monogenic
form of the disease that is associated with heterozygous
mutations in the g-secretase complex (Ingram, 2016). There
is an increased incidence of HS in the setting of other genetic
inflammatory syndromes, and multiple syndromic forms of
HS have been identified, such as pyoderma gangrenosum,
acne, and HS (PASH) and Dowling-Degos disease (DDD),
many of which have been tracked to specific mutations in a
small number of candidate genes (Scheinfeld, 2013). The
sporadic form of HS, in contrast to the familial form, appears
to encompass the majority of disease burden (60e70%) and
is thought to be driven by a polygenic architecture (Jfri et al.,
2019). Several unique phenotypes have even been identified
in both familial and sporadic HS and in certain endemic
populations (such as males of Asian ancestry) with clear ev-
idence of heritability (Pink et al., 2012; Wang et al., 2010; Xu
et al., 2016). Studies have found associations between envi-
ronmental factors and HS, which suggests a multifactorial
etiology. Whether specific genetic variations increase sus-
ceptibility to developing HS in the presence of specific
environmental triggers remains an open question and sug-
gests the existence of previously undescribed genetic risk
factors.
The paucity of HS GWASs has made systematic dissection
of HS pathophysiology challenging from a genetic level, and
because of its inflammatory nature, some have turned to
immune profiling for insights (Gudjonsson et al., 2020; Lowe
et al., 2020). Furthermore, a more complete understanding of
genetic features underlying HS may help to develop a more
nuanced classification system with better prognostic value,
improve patient management, and identify key candidate
therapeutics. To date, no genotypeephenotype correlation
has been established, but combined genetic and immuno-
logical studies could bridge the gap (Frew et al., 2019).
Although a minority of patients with HS exhibit family his-
tory, clinical, genetic, and molecular studies in familial co-
horts harboring g-secretase mutations began to define
pathological mechanisms involved in the etiology of HS.
Subsequent studies in laboratory animals further identify
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molecular mechanisms involved in HS. Together, GWASs
and laboratory studies have shown feasibility in dissecting
potential mechanisms of HS pathology. In this review, we
synthesize the current information on g-secretase genetics
underlying a subpopulation of patients with HS and evaluate
its importance in the context of disease pathobiology and
future research.
Mutations in g-secretase demonstrate clinical significance in
a subset of patients with HS
The g-secretase complex is a heterogenous transmembrane
protease complex composed of the catalytic PSEN1/PSEN2
and cofactor subunits PSENEN, NCSTN, and APH1A/APH1B.
It functions to cleave over 70 type I membrane proteins, such
as cadherins, Notch, and APP (Merilahti et al., 2017).
Dysfunctional g-secretaseeAPP axis is well known in the
development of Alzheimer disease; however, epidemiologic
studies to date have not identified an increased risk of Alz-
heimer among patients with HS with g-secretase complex
mutations or overlapping pathogenic variants between the
two disease populations (Garg and Strunk, 2017; Theut Riis
et al., 2017). Alzheimer- and HS-associated g-secretase mu-
tations may have distinct functional outcomes with regard to
downstream signaling and efficacy in cleaving different
substrates. More specifically, one could hypothesize that HS-
associated g-secretase mutations have no effect on the ability
of g-secretase to cleave APP or that these mutations are found
in isoforms not expressed in the brain.
In 2006, Gao et al. identified a putative risk locus within
1p21.1-1q25.3, a >900 gene region, in a four-generation
Chinese family using genome-wide linkage scan (GWLS)
(Gao et al., 2006). This was further narrowed to a >200 gene
region within 1q21.3-1q23.2 in a follow-up Chinese case
report. In a 2010 GWLS, Wang et. al. (2010) identified g-
secretase mutations in a cohort of six Han Chinese families
with an autosomal dominant transmission pattern that
harbored separate heterogenous rare variants in NCSTN,
PSEN1, or PSENEN, which localized to the 1q23.2 locus.
Gao et al. (2006) and Wang et al. (2010) represented two of
four genetic studies employing a genome-wide approach in
HS kindreds to date. The final two identified putative risk loci
at 1q23.2 (NCSTN) in an Iranian family and both chromo-
some 19 and 6q25.1-25.2 in a number of European families,
respectively (Faraji Zonooz et al., 2016; Irwin McLean et al.,
2006). In addition, a small number of other studies probing
African American, Indian, Japanese, British, and French
families identified g-secretase mutations that cosegregated
with a disease phenotype (Ratnamala et al., 2016; Takeichi
et al., 2020). The remainder of mutations were identified
via targeted sequencing; overall, 50 SNPs associated with HS
have been identified in Chinese (23), French (3), British (3),
Thai (3), and African Americans (1), encompassing the
NCSTN, PSEN1, and PSENEN genes (Table 1), 23 of which
were determined to be likely pathogenic by American Col-
lege of Medical Genetics criteria (Frew et al., 2017). The
locations of these mutations in g-secretase protein domains
are shown in Figure 1. Current population data indicate that
such heterozygous, nonsynonymous g-secretase mutations
are rarely found in healthy controls and demonstrate high
penetrance in affected pedigrees (Wang et al., 2010). Linkage
disequilibrium was identified in 12 pairs of variants, and two
specific mutations, NCSTN-R117X and -Q568X, were each
found in families from different races (Frew et al., 2019; Li
et al., 2019a).
Most of these g-secretase mutationepositive patients are
identified in families, often with multiple affected family
members. Of note, classification terms such as familial,
typical, atypical, syndromic, and sporadic are unreconciled
and require further validation (Frew et al., 2019). The ma-
jority of these patients are found in particular demographics
(e.g., male, Asian) and observed to have severe, widespread,
treatment-resistant, anatomically atypical, or syndromic dis-
ease with superimposed comorbidities, such as acne con-
globata, pyoderma gangrenosum, and hyperpigmentation,
among others (Pink et al., 2013). Comparisons against
existing HS classification systems demonstrate that g-secre-
tase mutationepositive patients, compared with patients with
sporadic HS, fit best with the categories of LC2 or follicle-
centered, atypical, nodular, and scarring folliculitis using
the Canoui, Naasan, Martorell-Calatayud, and van der Zee
classification systems, respectively (Canoui-Poitrine et al.,
2013; Ingram and Piguet, 2013; Martorell et al., 2020;
Naasan and Affleck, 2015; van der Zee and Jemec, 2015; Xu
et al., 2016). However, poor interrater reliability and the lack
of validation limit the utility of these classification systems
(van Straalen et al., 2018).
In the Alzheimer IDENTITY trial, semagacestat, a g-sec-
retase inhibitor, was administered but resulted in unspecified
skin toxicity in a large portion of patients (Henley et al.,
2014). More striking is that, in a subsequent study of pa-
tients with desmoid tumor, in which niragacestat, another g-
secretase inhibitor, was administered, 12 of 17 exhibited
adverse skin toxicities, and 6 of 7 evaluated by dermatology
exhibited new-onset, recurring follicular and cystic lesions with
surrounding inflammation in intertriginous areas, strongly
resembling the HS phenotype (O’Sullivan Coyne et al., 2018).
Biopsies of two patients showed inflamed follicular cysts, con-
firming pathology localized to the hair follicle (HF). These le-
sions then resolved on halting of treatment. These patients had
no personal or family history of HS or its commonly cited
comorbidities, suggesting that targeted g-secretase inhibition
can induce HS-like lesions, which supports the findings from
genetic studies identifying loss-of-function mutations in com-
ponents of the g-secretase complex.
g-secretase dysfunction leads to defective terminal HF
homeostasis
Occlusion of the follicular infundibulum because of mecha-
nisms including hyperkeratosis and disrupted epithelial dif-
ferentiation is considered the initiating event in HS
pathogenesis (Prens and Deckers, 2015), although some
believe subclinical inflammation may precede or even
contribute to the occlusion (Frew et al., 2018). Several studies
suggest that g-secretase may play a key role in occlusion.
Developmentally, the absence of g-secretase in mice is
known to convert HFs into epidermal cysts by altering the
differential fate of outer root sheath cells (Pan et al., 2004).
Several studies have linked impaired functionality of g-sec-
retase to the formation of HS-like lesions in mice. Condi-
tional knockout of g-secretase components results in many
G Vellaichamy et al.
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1 c.97G>A p.Gly33Arg Missense Japanese (1) (Takeichi et al.,
2020)
F Isolated HS Whole-exome
sequencing
2 c.223G>A p.Val75Ile Missense Chinese (1) (Zhang et al., 2013) F Isolated HS Targeted sequencing1




p.P73LFs*15 Frameshift Chinese (1) (Wu et al., 2018) F Isolated HS Targeted sequencing1
5 c.278delC p.P93LFSX15 Frameshift Chinese (1) (Li et al., 2018) C SAPHO Whole-exome
sequencing1
6 c.344_351del p.Thr115Asn*20 Truncating N/A (3) (Duchatelet et al., 2015) C PASH Targeted sequencing
7 c.349C>T p.Arg117X Truncating Chinese (1) (Wang et al., 2010) F (all) Isolated
HS (all)
GWLS1
Caucasian (1) (Liu et al., 2016) Targeted sequencing
African American (1) (Chen et
al., 2015)
Targeted sequencing
Japanese (1) Targeted sequencing
8 c.477 C>A p.C159X Truncating Chinese (1) (Savva et al., 2013) F Isolated HS Targeted sequencing1
9 c.487delC p.Gln163SerfsX39 Truncating French (3) (Miskinyte et al.,
2012)
F Isolated HS Targeted sequencing1
10 c.497C>A p. Ser166X Truncating Chinese (Ma et al., 2014) F Isolated HS Targeted sequencing
11 c.553G>A p.Asp185Asn Missense British (1) (Pink et al., 2013) C Isolated HS N/A
12 c.582þ1delG Splice site Splice site Japanese (1) (Nomura et al.,
2013)
F Isolated HS Targeted sequencing1
13 c.617C>A p.Ser206X Truncating Chinese (Shi et al., 2018) F Isolated HS Targeted sequencing1
14 c.632C>G p.Pro211Arg Missense Chinese (1) (Li et al., 2011) F Isolated HS Targeted sequencing1
15 c.647A>C p.Gln216Pro Missense Chinese (1) (Zhang et al., 2013) F Isolated HS Targeted sequencing1
16 c.687insCC p.Cys230ProfsX31 Frameshift Indian (1) (Li et al., 2011) F HS þ AC Targeted sequencing1
17 c.887A>G p.Pro296Arg Missense Chinese (1) (Xu et al., 2016) F Isolated HS Targeted sequencing
18 c.944C>T p.Ala315Val Missense Chinese (1) (Zhang et al., 2016) F Isolated HS Targeted sequencing
19 c.978delG p.M326IfsX30 Truncating Singaporean (Haines et al.,
2012)
F Isolated HS Targeted sequencing1
20 c.996þ7G>A Splice site Splice site Mixed European (1) (Pink et al.,
2012)
F Isolated HS Targeted sequencing1
21 c.1101þ1G>A Splice site Splice site Mixed European (2) (Pink et al.,
2011)
F Isolated HS Targeted sequencing1
22 c.1101þ10A>G Splice site Splice site British (1) (Pink et al., 2012) F Isolated HS Targeted sequencing1
23 c.1125þ1G>A Splice site Splice site British (1) (Pink et al., 2011) F Isolated HS Targeted sequencing1
24 c.1180-5C>G Splice site Splice site British (1) (Ingram et al., 2013) F (1)
S (2)
Isolated HS Targeted sequencing
25 c.1229C>T p.A410V Missense Caucasian (Liu et al., 2016) F Isolated HS Targeted sequencing
26 c.1258C>T p.Gln420X Truncating Singaporean (Haines et al.,
2012)
Chinese (Jiao et al., 2013; Yang
et al., 2015)
F Isolated HS Targeted sequencing1
27 c.1258C>T p.Arg429X Truncating Japanese (Nishimori et al.,
2017)
S Isolated HS Targeted sequencing
28 c.1300C>T p.Arg434X Truncating French (1) (Miskinyte et al.,
2012)
F Isolated HS Targeted sequencing
29 c.1352þ1G>A Splice site Splice site Chinese (1) (Liu et al., 2011) F Isolated HS Targeted sequencing1
30 c.1551þ1G>A Splice site Splice site Chinese (1) (Wang et al., 2010) F Isolated HS GWLS1
31 c.1635C>G p.Ala486
Thr517del
Truncating Iranian (1) (Faraji Zonooz et al.,
2016)
F PASH GWLS1
32 c.1695T>G p.Tyr565X Truncating Chinese (1) (Li et al., 2011) F Isolated HS Targeted sequencing1
33 c.1702C>T p.Gln568X Truncating Caucasian (1), Japanese (1)
(Nomura et al., 2014)
F Isolated HS Targeted sequencing1
34 c.1752delG p.Glu584AspfxX44 Truncating Chinese (1) (Wang et al., 2010) F Isolated HS GWLS1
35 c.1768A>G p.Ser590AlafsX3 Truncating French (Miskinyte et al., 2012) F Isolated HS Targeted sequencing1
36 c.1799delTG p.Leu600X Truncating Indian (1) (Li et al., 2011) F HS þ AC Targeted sequencing
(continued )
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histopathologic features of HS (He et al., 2019; Kamp et al.,
2011; Pan et al., 2004).
In vitro, haploinsufficiency of NCSTN in keratinocyte (KC)
cell lines upregulated the expression of type I IFN genes (Cao
et al., 2019). In molecular studies of familial HS, NCSTN defi-
ciency has been found to impact KC differentiation and prolif-
eration through several candidate pathways (He et al., 2020,
2019; Xiao et al., 2016). Six patients with HS and DDD, an HF-
centered pigmentary disorder, were found to possess PSENEN
mutations cosegregating with the unique phenotype and were
histopathologically distinguished from PSENEN
mutationepositive DDD-only patients by the presence of
follicular hyperkeratosis (Ralser et al., 2017), suggesting a po-
tential link between gene dysfunction and KC proliferation. A
study of HF KCs from 18 patients with HS (7 with family history,
11 without) found that they released greater levels of proin-
flammatory cytokines IL-1b, IP-10, and CCL5 when stimulated
in vitro, leading the authors to implicate an intrinsic proin-
flammatory KC phenotype in HS (Hotz et al., 2016). In addition,
a systematic review encompassing immunohistochemical data
from approximately 500 patients with HS demonstrated the
localization of IL-1b, IL-22, IL-36, and IL-37 with KCs and
highlighted the intimate relationship between the proin-
flammatory milieu and dysregulated hyperkeratosis (Frew et al.,
2018). The abovementioned data on NCSTN and PSENEN
suggest that g-secretase dysfunction may be linked to HS-
associated follicular disruption by mechanisms localized to
KCs. The g-secretase inhibitoreinduced, pathologically
confirmed folliculocystic lesions in healthy individuals
regressed after cessation, which supports a role for g-secretase
as a potential target for treatment in at least a subset of patients.
The predominance of loss-of-function mutations implicates
haploinsufficiency as a likely mechanism of g-secretaseein-
duced disease in familial HS (Wang et al., 2010; Yang et al.,
2015). However, the presence of missense mutations in both
sporadic (4) and familial (6) cases and conflicting results from
translational biology may implicate altered functional enzy-
matic activity. Loss of a single Psen1 allele in mice does not
produce skin disorders and only occurs with more severe
reduction in presenilin expression. Wild-type (WT) mice
treated with a g-secretase inhibitor, which maintained levels
of g-secretase but specifically inhibited its enzymatic activity,
produced similar epidermal abnormalities to Ncstnþ/ mice,
including follicular hyperkeratosis and inclusion cyst forma-
tion (Li et al., 2007). Another study of Ncstn/ mice and
Ncstn/ Psen1/ mice found that both developed follicular
inclusion cysts compared with WT, but the double-knockout
mice developed these lesions earlier, and this was dependent
on the level of g-secretase (O’Brien and Wong, 2011). In vitro
study of human tissue from patients with HS harboring g-
secretase mutations found that membrane expression of
g-secretase was unchanged despite reduction in cellular
protein expression (Table 1) (Pink et al., 2016), which may be
due to physiologic post-transcriptional selection of <5% of
fully assembled complexes that are then localized to the
membrane (Yang et al., 2019). It seems likely that patients
with only a partial loss of function may still produce enough

















Frameshift Dutch (Vossen et al., 2020) F Isolated HS Whole-genome and
targeted sequencing
PSENEN e 19q13.12
1 c.168T>G p.Tyr56X Truncating Ashkenazi Jewish (4) (Pavlovsky
et al., 2018)
F DDD Targeted sequencing1
2 c.167-2A>G Splice site Splice site Chinese (Zhou et al., 2016) F DDD Targeted sequencing1
3 c.194T>G p.Leu65Arg Missense Chinese (Zhou et al., 2016) F DDD Targeted sequencing1
4 c.66delG p.Phe23Leu fsX46 Truncating Chinese (Liu et al., 2016; Wang
et al., 2010)
F Isolated HS Targeted sequencing
5 c.66_67insG p.Phe23ValfsX98 Truncating British (1) (Pink et al., 2011) F Isolated HS Targeted sequencing
6 c.279delC p.Phe94SerfsX51 Truncating Chinese (Pink et al., 2012) F Isolated HS Targeted sequencing
7 c.84_85insT p.L28FfsX93 Insertion Thai (2) (Li et al., 2019b) F DDD Targeted sequencing1
8 c.62-1G>C Exon 2 Splice site Indian (2) (Ralser et al., 2017) F DDD Targeted sequencing1
9 g.1412T>C Splice site Splice site French (Ralser et al., 2017) F DDD Targeted sequencing1
10 c.35T>A p.Leu12X Truncating German (2) (Ralser et al., 2017) F DDD Targeted sequencing1
11 c.115C>T p.Arg39X Truncating German (1) (Ralser et al., 2017) F DDD Targeted sequencing1
PSEN1 e 14q24.2
1 c.725delC p.Phe242LeufsX11 Truncating Chinese (3) (Wang et al., 2010) F Isolated HS GWLS1
2 c.837þ16G>T Splice site Splice site Chinese (Lazic et al., 2012) C Isolated HS Targeted sequencing
3 c.953A>G p.Glu318Gly Missense British (3) (Ingram et al., 2013) F Isolated HS Targeted sequencing1
Abbreviations: AC, acne conglobata; C, case; DDD, Dowling-Degos disease; F, familial; GWLS, genome-wide linkage scan; HS, hidradenitis suppurativa; N/
A, not applicable; No., number; PASH, pyoderma gangrenosum, acne, and hidradenitis suppurativa; SAPHO, synovitis, acne, pustulosis, hyperostosis, and
osteitis.
1Controls were used.
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above a certain threshold. Any reduction in the level of
functional protein or g-secretase activity or increasing the
threshold may subsequently elicit a clinical phenotype
(Melnik and Plewig, 2013). A recent study identified a new
NCSTN mutation causing HS in a Dutch family. The associ-
ated immunobiological functions of NCSTN and its coex-
pressed genes ARNT and PPARD link genetics to the most
common environmental and metabolic HS risk factors,
smoking and obesity (Vossen et al., 2020). This raises the
question, how do environmental factors increase the risk of
developing HS in those that harbor g-secretase mutations?
Emerging studies have provided import data supporting this
stance. A systematic review and in silico analysis of 34 HS g-
secretase mutations predicted structural alterations in
substrate recruitment sites, catalytic domains, and post-
translational modifications, consistent with altered enzy-
matic activity and substrate processing (Li et al., 2019a). A
second, more extensive in silico analysis bolstered these re-
sults by showing that 39 pathogenic familial HS-associated g-
secretase mutations underwent significant structural changes
in known sites of substrate binding and cleavage, either
through nonsense-mediated decay (23) or altered binding
affinity (16) (Frew and Navrazhina, 2019). Such changes were
found to be distinct from those found in Alzheimer-associated
g-secretase mutations (Frew and Navrazhina, 2019; Li et al.,
2019a). One studied HS PSEN1 mutation was found to affect
the opposite side of the transmembrane-5 domain from the
affected sites of reported Alzheimer mutations (Frew and
Navrazhina, 2019). Such mechanistic differences and the
myriad of g-secretase substrates may shed light on the lack of
co-occurrence between the familial forms of Alzheimer and
HS despite overlapping loci.
g-secretase may act through multiple secondary pathways,
such as Notch, phosphoinositide-3-kinase, and EGFR
Isolation of g-secretaseedependent pathways specific to HS
genesis is complicated by the large number of known g-
secretase substrates, the pleiotropy of its components, and the
lack of a reliable animal model for in vivo study. Thus,
although the following pathways are the most well described,
many likely remain undiscovered.
The Notch pathway has gained attention in HS because of
its role in maintaining the HF stem cell pool and functional
regulatory T cells (Treg) in the HF and promoting antimicro-
bial defenses at the epidermis (Sabat et al., 2020). In the skin,
Notch normally maintains stemness in the HF stem cells, and
disruption of signaling leads to aberrant differentiation and
proliferation of KCs and their precursors. Tregs are required
for development and maintenance of the HF (Ali et al., 2017)
and immunological balance in the skin, both of which Notch
Figure 1. Locations of confirmed mutations in g-secretase protein domains.
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signaling supports. Finally, studies have shown an essential
role for Notch in supporting T cellederived IL-22, which
maintains the skin microbiome (Sabat et al., 2020). These
roles might explain why g-secretase mutations that influence
Notch signaling can elicit the diverse aberrations seen in HS
skin lesions (e.g., follicular cystic formation, inflammatory
immune cell infiltration, and altered skin microbiota).
Notch 1e4 are well-characterized targets of g-secretase,
and controlled disruption of Notch pathway components in
mice results in epidermal and follicular aberrations that
resemble histopathological findings in HS (Pink et al., 2012).
Although some Notch molecules are abnormally expressed in
HS tissue and HaCaT cells with g-secretase mutations (Li
et al., 2019a; Xiao et al., 2016), minimal evidence exists
that indicates that Notch aberrations are specific to HS or of
sufficient statistical significance to be considered risk-
associated loci for disease development (Frew et al., 2019).
Functional assessment of four NCSTN missense mutations
found that three maintained downstream Notch signaling
whereas the fourth did not, casting doubt on the assumption
that Notch-dependent pathways drive monogenic HS (Zhang
and Sisodia, 2015). In silico and gene expression analyses of
identified pathogenic mutations have failed to identify Notch
as a specific marker of HS (Blok et al., 2016; Frew and
Navrazhina, 2019), and genotypeephenotype correlation
revealed no significance between impact on Notch signaling
and HS phenotype (Frew et al., 2019). A recent study
demonstrated that mRNA levels of NCSTN, Notch, and
phosphoinositide-3-kinase (PI3K)/protein kinase B are over-
expressed in lesional HS skin versus controls, and there is no
association between positive family history and mRNA levels
(Hessam et al., 2020). The lack of direct evidence from ani-
mal models or human studies makes the role of Notch in HS
controversial, suggesting that other pathways play a role in
the molecular pathogenesis of HS.
Abnormalities in the PI3K and EGFR pathways have pre-
viously been linked to epidermal and follicular dysfunction
(Zhang et al., 2007), and emerging studies suggest that these
pathways interact with microRNAs to play a role in familial
HS pathogenesis. NCSTN knockdown in HaCaT cells led to
decreased keratinocyte miR-100-5p, a microRNA that was
previously found to be downregulated in patients with fa-
milial HS, which then resulted in increased PI3K and KC
hyperproliferation (He et al., 2020; Xiao et al., 2016). He
et al. (2019) found that NCSTN mutations lead to reduced
miR-30a-3p levels, which increases RAB31 expression owing
to diminished negative regulation, and this increase in
RAB31 accelerates the degradation of activated EGFR on
KCs, leading to abnormal differentiation. In silico assessment
of pathogenic g-secretase mutations found that HS-
associated ERBB4, SCN1B, and TIE1 were differentially
expressed and that this was specific to HS when compared
with other inflammatory dermatoses to account for back-
ground cutaneous inflammation (Frew and Navrazhina,
2019).
Questioning the role of g-secretase: Future work
Many HS experts cite the poor understanding of disease
pathobiology as a significant bottleneck for HS management
and a critical area for future work (Hoffman et al., 2017).
Despite the myriad of discovered variants, only a minority
(<5%) of patients with HS have been found to harbor the
monogenic g-secretase mutationeassociated familial HS
phenotype, far fewer than even the 30e40% reporting family
history. A recent key study of a predominantly Caucasian
cohort of 188 patients with HS found that just 6.4% had
mutations in g-secretase (Duchatelet et al., 2020). Overall,
the majority of patients with HS studied to date are found
negative for g-secretase mutations when assessed by targeted
sequencing (Frew et al., 2017; Ingram et al., 2013; Pink et al.,
2012). Although many pathogenic variants cosegregate with
the HS phenotype in familial kindreds, others do not and
indicate a benign nature (Al-Ali et al., 2010; Jarvik and
Browning, 2016; Nomura et al., 2014). The sole whole-
genome expression profiling study done on patients with
HS found no difference in whole-blood mRNA expression in
NCSTN, PSEN1, or PSENEN between HS and healthy con-
trols, although a small sample size was studied and no vali-
dation was performed (Blok et al., 2016). Most of the disease
burden is in sporadic HS (60e70%), yet few studies have
been performed in this population robust enough to probe its
polygenic architecture and identify low to moderate impact
variants and their attributable risks.
The view that HS has a polygenic foundation has subse-
quently gained traction, supported by strong, well-
documented associations with other chronic inflammatory
disorders, including inflammatory bowel disease, spondy-
loarthropathy, lupus, and pyoderma (Deckers et al., 2017;
van der Zee et al., 2016; Vekic et al., 2016). Numerous genes
besides g-secretase components have also been identified to
associate with HS, including connexin-26, fibroblast GF re-
ceptor, and inositol polyphosphate-5-phosphate (Tricarico
et al., 2019), albeit with variable phenotypes. The racial
predisposition toward African Americans is also important;
given that disparate risks in immune-mediated disease
development and variable responses to treatment of such
conditions can, at least in part, be traced to ancestral het-
erogeneity (Nédélec et al., 2016), similar assessments in HS,
particularly large-scale, hypothesis-free approaches such as
GWAS, may be worthwhile.
A small number of studies have employed this approach
with promising results. A pharmacogenomics GWAS of the
Pioneer I and II trials found a single variant in BCL2 that
was associated with response to adalimumab in patients
with HS in a TNF-dependent matter localized to the
follicular unit (Liu et al., 2020). Sequence investigation of
the IL12RB1 receptor subunit gene identified two haplo-
type groups associated with significant differences in age at
disease presentation, stage of disease, and number of skin
areas (Giatrakos et al., 2013). Similar analysis of the TNF
gene found significant association between SNPs of the
promoter region and susceptibility to HS, disease course,
and response to TNF antagonists (Savva et al., 2013). A
study of two independent cohorts (total N ¼ 261) show-
cased that high copy number (>6) of the DEFB cluster was
associated with a markedly increased OR (6.72 after meta-
analysis, P < 0.0001) for HS development and fewer than
six copies was linked with earlier onset, fewer skin local-
izations, and less frequent purulence (Giamarellos-
Bourboulis et al., 2016).
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Nonetheless, the several identified HS mutations in
NCSTN, PSENEN, and PSEN1, many of which were deter-
mined to be causative in familial HS, and their demonstrated
relevance at the clinical and pathobiological levels advocate
for continued investigation into g-secretase. The establish-
ment of guidelines for conducting the necessary multi-
institutional studies, particularly genotypeephenotype
analysis and exome sequencing of affected kindreds repre-
sentative of the broader HS population, has already been
undertaken and is a step in the right direction (Byrd et al.,
2019). Conducting larger, prospective studies of patients
with familial HS that include clinical data collection for
rigorous phenotyping will provide more data to establish a
reliable, unbiased classification system. HS remains a clinical
diagnosis with only anecdotal evidence for the use of bio-
markers, histopathologic findings, and objective diagnostics.
Yet, when approached clinically, the lack of awareness,
embarrassment in discussion, low socioeconomic status
among patients, lack of follow-up because of increased use of
emergency and inpatient care, and dearth of HS specialists in
the United States all serve as barriers to obtaining accurate
clinical information from patients with HS (Hoffman et al.,
2017). At the experimental level, establishing relevant ani-
mal disease models, designing translational studies aimed at
distinguishing among the many contributing mechanisms to
HS, and performing functional validation of identified vari-
ants are key tasks in this process.
In conclusion, here we review the available literature on g-
secretase in HS and evaluate its evidence in the context of
clinical, epidemiologic, pathobiological, and molecular
studies. The release of ENCODE 3 and its associated tools
poises future studies in HS to uncover important genetic and
epigenetic features that may further clarify the etiologies of
HS (ENCODE Project Consortium et al., 2020). Studying the
g-secretase complex and the greater genetic architecture of
HS will allow for markedly improved and individualized
treatment for individuals with this debilitating disease.
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